Status:
RECRUITING
Respiratory Microbiota and Immune Response in CVID
Lead Sponsor:
Boston University
Collaborating Sponsors:
Takeda
Conditions:
CVID
Eligibility:
All Genders
18-80 years
Brief Summary
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease dev...
Eligibility Criteria
Inclusion
- Patients with primary antibody deficiency diagnosed by their treating physician
- Controls will not have a diagnosis of immunodeficiency of any sort
- Male and female patients will be enrolled evenly
Exclusion
- Patients who self identify as pregnant
- Patients with asthma or chronic obstructive pulmonary disease (COPD) that are not well controlled clinically
Key Trial Info
Start Date :
March 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06173128
Start Date
March 15 2024
End Date
February 1 2026
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Medical Center
Boston, Massachusetts, United States, 02118